Krystal Biotech, Inc.
KRYS
$346.17
-$1.92-0.55%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 22.63% | 25.15% | 33.95% | 54.51% | 116.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 22.63% | 25.15% | 33.95% | 54.51% | 116.09% |
| Cost of Revenue | -0.89% | 7.38% | 14.89% | 19.03% | 106.79% |
| Gross Profit | 24.30% | 26.44% | 35.36% | 57.36% | 116.78% |
| SG&A Expenses | 25.23% | 29.01% | 29.12% | 27.50% | 24.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.15% | 19.42% | 21.65% | 21.66% | 27.74% |
| Operating Income | 30.10% | 33.72% | 56.25% | 143.72% | 3,674.47% |
| Income Before Tax | 34.29% | 50.21% | 98.70% | 225.68% | 55.70% |
| Income Tax Expenses | -167.40% | -225.99% | -347.88% | -337.75% | 801.97% |
| Earnings from Continuing Operations | 64.57% | 81.53% | 129.74% | 279.80% | 38.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 64.57% | 81.53% | 129.74% | 279.80% | 38.50% |
| EBIT | 30.10% | 33.72% | 56.25% | 143.72% | 3,674.47% |
| EBITDA | 29.95% | 32.71% | 54.14% | 134.60% | 1,939.39% |
| EPS Basic | 62.39% | 79.56% | 127.79% | 275.94% | 35.29% |
| Normalized Basic EPS | 23.14% | 25.67% | 41.20% | 94.94% | 440.38% |
| EPS Diluted | 62.07% | 79.63% | 128.75% | 277.27% | 34.98% |
| Normalized Diluted EPS | 22.98% | 26.02% | 41.86% | 95.51% | 439.69% |
| Average Basic Shares Outstanding | 1.45% | 1.18% | 1.23% | 1.45% | 1.85% |
| Average Diluted Shares Outstanding | 1.54% | 0.88% | 0.83% | 1.43% | 2.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |